Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Leukemia. Author manuscript; available in PMC 2010 July 1.
Published in final edited form as:
Published online 2009 September 17. doi:  10.1038/leu.2009.189
PMCID: PMC2806506

TP53 Mutations in Myeloid Malignancies are either Homozygous or Hemizygous due to Copy Number-Neutral Loss of Heterozygosity or Deletion of 17p

Our previous studies demonstrated that single nucleotide polymorphism arrays (SNP-A), applied as a karyotyping platform, complement traditional metaphase cytogenetics (MC) and improve the diagnostic yield of cytogenetic studies because SNP-A can more precisely resolve smaller genetic defects and allow for detection of copy number-neutral loss of heterozygosity (CN-LOH), a defect frequently found in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Like balanced translocations, CN-LOH represents a chromosomal abnormality that occurs without a concurrent change in gene copy number (CN). CN-LOH is an increasingly recognized chromosomal mechanism by which homozygous somatic mutations may be acquired during evolution of hematologic malignancies and can pinpoint the location of such gene(s); examples include CEBPA, FLT3, WT1, RUNX1, JAK2, and NF11.

Deletions involving the short arm of chromosome 17, detectable by MC in MDS and AML, may be associated with a complex karyotype that includes -5/5q- and/or -7/7q-; such patients have a poor prognosis2. The well known tumor suppressor gene TP53, located at 17p13.1, is a likely candidate gene contributing to the disease phenotype following mutation of one or both alleles. Mutations may be linked to loss of 17p by chromosomal or submicroscopic deletion LOH (mut/-) or may occur in the absence of 17p loss in either heterozygous (wt/mut), biallelic (mut1/mut2) or homozygous (mut1/mut1) forms through CN-LOH. Although mutations in TP53 are frequent in solid tumors, the mutation frequency reported in hematologic malignancies is much lower2.

We have applied high-density Affymetrix 250K and 6.0 SNP-A to identify LOH of chromosome 17 in a large cohort of patients (N=379) with MDS, MDS/MPN and primary and secondary AML. We noted that advanced forms of MDS and AML often harbored areas of LOH (deletion and CN-LOH) involving the short arm of chromosome 17 (Supplemental Table1 and Table 2).

In total we identified 21 (5.5%) patients with LOH17p on chromosome 17. Deletions (-17/17p-) were found in 14 (3.7%) and somatic CN-LOH17p in 7 (1.8%) patients by SNP-A. We defined a commonly deleted region (CDR) on chromosome 17p (Figure 1A). The CDR at 17p13.1 (bp 6,828,482 to 8,075, 871; 1.25 Mb) contained TP53, among others genes, and was present in 12/14 patients with del(17p). In two patients del(17p) did not span the TP53 locus, suggesting that other genes located in these regions, such as CRK or HIC1, may be involved in disease pathogenesis. Somatic CN-LOH17p was detected in 7 patients. The average size of CN-LOH17p detected by SNP-A was 12.1± 5.5 Mb. The somatic origin of CN-LOH17p was confirmed by analysis of a control cohort consisting of 1003 individuals which did not reveal any cases of CN-LOH involving 17p, suggesting that large subtelomeric CN-LOH17p represents an acquired lesion. In addition, SNP-A was performed on paired CD3+ cells for exemplary cases of del(17p) and CN-LOH17p to confirm the somatic nature of these lesions (Figure 1B).

Figure 1
(A) Summary of LOH17p detected by SNP-A. Lesions of chromosome 17p detected by SNP-A for individual patients are shown (N=21). Blue bars indicate deleted regions. Red bars designate areas of acquired somatic copy neutral loss of heterozygosity (CN-LOH). ...

Comparison of the clinical characteristic of 21 patients with LOH17p revealed that these patients shared similar features including a complex karyotype and a strong association between LOH17p and abnormalities of chromosomes 5 and/or 7. Also, the majority of the 21 patients with LOH17p by SNP-A had aggressive histomorphologic features (10 secondary AML, 2 primary AML, 1 t-AML, 1 RAEB-1, 3 RAEB-2, 3 RCMD-RS, 1 RCMD) and a poor prognosis with a median survival of only 6 months for patients with del(17p) and 3 months in case of patients with CN-LOH17p (Figure 1C).

The identification of several cases with overlapping CN-LOH17p led us to hypothesize that TP53 mutations would be present in these patients. Overall, 19/21 instances of LOH17p included the TP53 locus: 7 were CN-LOH and 12 were deletions (Figure 1A). DNA was available for 15/19 of these patients. We found homozygous TP53 mutations in 5/6 patients (83%) with somatic CN-LOH and hemizygous TP53 mutation in 7/9 patients (78%) with del(17p) (Figure 1D). Of 12 TP53 mutations found, 11 (92%) were missense and located in the DNA-binding core domain (residues 102–292) of TP53 (4 in exon 5: C141Y; V172F; C176Y; H179Q; 2 in exon 6: H193N, H193R; 1 in exon 7: R249G and 4 in exon 8: V272L, V272M, 2R273H twice; Table 13). One homozygous frameshift/nonsense mutation was found in exon 9. Overall, TP53 mutations were found in 12 of 15 cases (80%) with LOH in the TP53 locus. To compare the rate of TP53 mutations in MDS/AML patients with and without chromosome 17 aberrations by either MC or SNP-A, we screened an additional 40 patients with MDS or AML. Five had a normal karyotype, 14 had a complex karyotype (9/14 with aberrations of chromosomes 5, 7, or both; and 5/14 without aberrations of 5 or 7), 7 had sole -7/7q-, 4 had sole 5q- and 10 had -5/5q- or -7/7q- with other abnormalities. We found only two heterozygous mutations (M273I, R248Q) in these patients; in both cases the patients had a complex karyotype with -5/5q- and -7/7q- without LOH17p. Of interest, one of these patients transformed from aplastic anemia (AA) to AML. For this patient we were able to partially reconstruct the time of mutation occurrence. Five months after diagnosis with AA, SNP-A detected a minor clone with monosomy 7. At this time there was no sign of TP53 mutation. Two years after AA diagnosis the patient developed AML. At this time, analysis of bone marrow by MC and SNP-A showed a complex karyotype and a heterozygous mutation of TP53 was found.

Table 1
Characteristics of TP53 mutations found in patients with LOH17p identified by SNP-A

In our cohort of 379 patients 11.6% of cases had a complex karyotype (in our study complex karyotype was defined as three or more chromosomal aberrations) and, of these, 45% also had LOH17p. Only one patient without a complex karyotype had LOH17p. In cases with a complex karyotype and LOH17p, -5/5q- and/or -7/7q-, TP53 mutations were frequent (75%). TP53 mutations were much less frequent (2/40; 5%) in patients without aberrations of chromosome 17 by either MC or SNP-A (Figure 1D). These results are concordant with previous report showing complete or partial loss of 17p in 4.3% of 1138 MDS/AML patients. In 69% of those patients a TP53 mutation was found as compared to a frequency of TP53 mutation of 3.1% in patients without abnormalities of chromosome 172.

Our findings emphasize the validity of Knudson’s classic two-hit model of tumorigenesis in which tumor suppressor genes such as TP53 must undergo inactivation of both alleles to permit tumor formation4. In this context, we propose two mechanisms by which both TP53 alleles may be inactivated. In the case of deletion 17p, one allele becomes inactivated by mutation and the wild-type allele is lost through deletion. In patients with CN-LOH17p, one more step can be considered: reduplication of the mutated TP53 allele as a result of an attempt to correct for the lost chromosomal material. Indeed, this mechanism has been proposed to explain homozygous TP53 mutations in patients with apparently normal chromosomes 17 and two FISH signals for TP535. Our results suggest that intragenic TP53 mutation preceded LOH17p, based on the fact that we found two patients with heterozygous TP53 mutations without the presence of LOH17p by MC or SNP-A. It is likely that such patients would show disease progression associated with subsequent 17p deletion or somatic CN-LOH17p, either of which would lead to loss of the protective wild-type allele.

A high frequency of TP53 mutations in at least a partially heterozygous constellation has been described in AML with a complex karyotype2;67. However, since neither SNP-A nor microsatellite analyses were performed in these studies, we suggest an alternative explanation: that identical findings could occur if DNA were isolated from a mixture of normal and abnormal cells, where a clone of cells with CN-LOH17p is the source of the homozygous mutated allele and admixed normal cells are the source of the wild-type allele. We and others2;67 have shown that TP53 mutations occur frequently in MDS/AML patients with complex karyotype, especially with del17p, del5/5q and del7/7q and are very rare in patients with other cytogenetic abnormalities. Our results point towards the presence of homozygous mutations in the context of CN-LOH17p while previous studies demonstrated the presence of hemizygous mutations. Our study explains why in the former studies patients with del5/5q- and del7/7q- showed TP53 mutations without obvious del17p: they may have had CN-LOH17p. We have proceeded to sequence patients without del17 (with and without del5/5q and del7/7q) and found 2 mutations in 40 (5%) patients; in a previous work in which such patients were sequenced, only 8/256 (3.1%) mutations were found, likely associated with CN-LOH17p for which they were not screened2. A high incidence of TP53 mutation in MDS/AML patients with complex cytogenetics with deletions of chromosomes 5, 7 and 17 suggests a cooperative effect between these lesions. This non-random pattern of DNA losses in MDS/AML patients with a complex karyotype is of interest, and suggests the presence of a multi-step pathway which is responsible for the sequential accumulation of certain chromosomal aberrations that results in poor clinical outcome8.

In sum, our study demonstrates that CN-LOH17p is a frequent type of cytogenetic defect occurring in patients with advanced MDS and sAML with a complex karyotype and is strongly associated with homozygous TP53 mutations. As described in previous reports, hemizygous deletions affecting this locus have been associated with mutation in the remaining TP53 allele. Previously, detection of TP53 mutations in patients without a visible cytogenetic deletion in this region prompted the assumption that these mutations were heterozygous2;67. However, our study indicates that in MDS/sAML, TP53 mutations can occur in either a hemizygous or homozygous constellation and heterozygous mutations are actually very rare as previously reported in large cohort of patients2. Clinically, prognosis of patients with CN-LOH17p is as poor as that of patients with del17p. LOH17p is strongly associated with a complex karyotype in combination with whole or partial losses of chromosomes 5 and 7, and hemi- or homozygous TP53 mutations. Complex karyotypes with 5q and 7q abnormalities without del(17p) often harbor CN-LOH17p, a lesion which is cryptic unless analyzed by SNP-A.

Supplementary Material


This work was supported in part by RO1HL-082983, U54 RR019391 K24 HL-077522 and by Grant from AA&MDS International Foundation and Robert Duggan Charitable Fund (J.P.M.).


Supplementary information accompanies the paper on Leukemia website (

Conflict of interest The authors declare no conflict of interest

Reference List

1. Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood. 2008;112:965–974. [PubMed]
2. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P, et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia. 1995;9:370–381. [PubMed]
3. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622–629. [PubMed]
4. Wilentz RE, Argani P, Hruban RH. Loss of heterozygosity or intragenic mutation, which comes first? Am J Pathol. 2001;158:1561–1563. [PubMed]
5. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol. 2001;19:1405–1413. [PubMed]
6. Bowen D, Groves MJ, Burnett AK, Patel Y, Allen C, Green C, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia. 2009;23:203–206. [PubMed]
7. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia. 2008;22:1539–1541. [PubMed]
8. Alvarez S, Cigudosa JC. Gains, losses and complex karyotypes in myeloid disorders: a light at the end of the tunnel. Hematol Oncol. 2005;23:18–25. [PubMed]